The failure of a gentamicin-containing collagen sponge called Cogenzia to deliver statistically significant improvements in clinical cure rates for patients with diabetic foot infections during twin phase III studies sunk shares of Innocoll Holdings plc (NASDAQ:INNL) on Friday, driving them 17.4 percent lower to a $2.89 close after touching a 52-week low.